Laurus Labs shares jumped 4.05% to Rs 1,666 in Monday’s trading session after the company reported a stellar performance for the June 2026 quarter. The rally was fueled by a 126% year-on-year surge in net profit and 29% revenue growth, driven by strong CDMO performance and steady demand for affordable medicines.
According to the company’s regulatory filing, consolidated net profit for Q1FY27 stood at Rs 368 crore, compared with Rs 163 crore in the same quarter last year, marking a sharp 126% YoY growth. Revenue from operations increased 29% year-on-year to Rs 2,026 crore from Rs 1,570 crore in the corresponding period.